NOAC Reversal Agent Effective in Study

ACC Conference Reporter

ESC Congress 2016 | ROME — A novel compound designed to reverse any of the newer oral anticoagulants targeting Factor Xa appears to do just that, a finding that may be cold comfort a week after the FDA said it wants more evidence before it can approve the drug. Read More >>>

Keywords: ESC Congress

< Back to Listings